Use the search to find what you are looking for




09 Jan 2018

We have been pressing the Quality Surveillance Team to release the report on the external peer review that took place in 2016. The latest from the Deputy Head of the Quality Surveillance Team is that ‘The report will be available to NHS England colleagues and stakeholders at the end of January beginning of February 2018. It is currently being prepared.’

12 Dec 2017

ESMO have produced a useful patient-oriented guide on immunotherapy side effects ESMO-Patient-Guide-on-Immunotherapy-Side-Effects

22 Nov 2017 09 Nov 2017

An interesting short article in NEJM here . Particularly relevant as we work on the development of a Patient Decision Aid for CUP. The concluding paragraph gives a flavor: “Regret is typically viewed as a negative emotion. It is notable that existing patient regret scales have largely failed to assess for a positive impact of regret. However, awareness of regret canRead more

30 Oct 2017

Pharmaceutical company Roche is to sponsor a multi-country, Phase II, genomic profiling study to evaluate the efficacy of molecularly guided therapy versus platinum chemotherapy in CUP patients. Profiling will be based on the FoundationOne® assay. It is intended that the trial should open in approximately 100 sites in 25 countries and will enroll 790 patients. Last week it was agreed,Read more

14 Oct 2017

A very exciting PhD research project has started at the Cancer Research UK Manchester Institute. CRUK Clinical research fellow, Dr Alicia Conway, is to test the hypothesis that liquid biomarkers, including but not limited to ctDNA, circulating tumours cells (CTCs) and tumour educated blood platelets, can be used to detect tissue of origin and molecular subtypes in patients with carcinomaRead more

11 Oct 2017

Perhaps a bit ‘left field’ but interesting for its similarities with humans, an article on CUP in dogs by Rossi et al can be found here on PubMed. This is the abstract: The aim of this retrospective study was to describe clinical features, treatment and outcome of 21 dogs with metastatic cancer of unknown primary (MCUP), a biopsy-proven malignancy beingRead more

06 Oct 2017

At the recent ESMO 2017 conference Caris Molecular Intelligence (CMI) presented 2 posters on clinical benefit and utility that may be of interest – the details below are provided by Caris: 1. Comparison of progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS on prior therapy: a pooled analysis from 4 contemporary prospective studies. Summary: • In total, 202Read more

30 Sep 2017

Patient experience research is vital to the understanding of how CUP patients can be managed best. A paper – which explores the differences between patients with known versus unknown cancers – is published this week in BMJ Open Volume 7, Issue 9: Differences in experiences of care between patients diagnosed with metastatic cancer of known and unknown primaries: mixed-method findings fromRead more

23 Sep 2017

Our 10th anniversary Awareness Week campaign is ’10 x more‘. Please support us by making 10 times more people aware of the disease. # CUP is the 5th commonest cause of cancer death in the UK (after lung, bowel, breast, prostate) # 24 new cases of CUP are diagnosed every day in the UK (Ratio of 1 male to 1.2Read more